Delving into the Latest Updates on Juvantia Pharma Oy with Synapse

A Phase II, Randomised, Placebo-Controlled, Double-Blind, Replicated Crossover, Pilot Study on the Effect of Fipamezole on Neurogenic Orthostatic Hypotension in Patients with Multiple System Atrophy or Parkinson’s Disease - FOEHN

开始日期2008-10-07

申办/合作机构

Juvantia Pharma Oy

NCT00758849 / Unknown status临床2期

A Phase II, Randomised, Placebo-Controlled, Double-Blind, Replicated Crossover, Pilot Study on the Effect of Fipamezole on Neurogenic Orthostatic Hypotension in Patients With Multiple System Atrophy or Parkinson's Disease

The purpose of this study is to determine whether Fipamezole is effective in the treatment of orthostatic hypotension and related symptoms in multiple system atrophy and Parkinson's disease.

开始日期2008-09-01

申办/合作机构

Juvantia Pharma Oy

[+1]

NCT00559871 / Completed临床2期

A Phase II, Randomized, Double-Blind, Placebo-Controlled, Dose Response Study of the Efficacy, Safety and Tolerability of Fipamezole as an Oromucosal Fast Dissolving Tablet in the Treatment of Parkinson's Disease Patients.

The purpose of this study is to determine whether Fipamezole is effective in the treatment of levodopa-induced dyskinesia in advanced Parkinson's disease.

开始日期2007-10-01

申办/合作机构

Juvantia Pharma Oy

[+1]

100 项与 Juvantia Pharma Oy 相关的临床结果

登录后查看更多信息

0 项与 Juvantia Pharma Oy 相关的专利（医药）

登录后查看更多信息

100 项与 Juvantia Pharma Oy 相关的药物交易

登录后查看更多信息

100 项与 Juvantia Pharma Oy 相关的转化医学

登录后查看更多信息